Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 25, Issue 3, Pages 67-76Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-023-01080-8
Keywords
ApoC-III; Triglyceride-rich lipoproteins (TRLs); Cardiovascular disease burden; Post prandial lipemia; Therapeutic target
Categories
Ask authors/readers for more resources
This review summarizes the different functions of Apolipoprotein C-III (ApoC-III) and highlights its multifaceted pathophysiological role. ApoC-III plays an important role in HDL metabolism and the development of atherosclerosis, inflammation, and ER stress. It is also linked to cardiovascular disease risk and progression of coronary artery disease, and recent clinical trials suggest that inhibiting ApoC-III may be a promising approach for managing hypertriglyceridemia and preventing cardiovascular disease.
Purpose of ReviewApolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. This review summarizes the different functions of ApoC-III and underlines the recent findings related to its multifaceted pathophysiological role.Recent FindingsThe role of ApoC-III has been implicated in HDL metabolism and in the development of atherosclerosis, inflammation, and ER stress in endothelial cells. ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia (PPT). The emerging evidence of the involvement of ApoC-III in the in the pathogenesis of Alzheimer's disease open the way to further study if modification of ApoC-III level slows disease progression. Furthermore, ApoC-III is clearly linked to cardiovascular disease (CVD) risk, and progression of coronary artery disease (CAD) as well as the calcification of aortic valve and recent clinical trials has pointed out the inhibition of ApoC-III as a promising approach to manage hypertriglyceridemia and prevent CVD.Several evidences highlight the role of ApoC-III not only in triglyceride metabolism but also in several cardio-metabolic pathways. Results from recent clinical trials underline that the inhibition of ApoC-III is a promising therapeutical strategy for the management of severe hypertriglyceridemia and in CVD prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available